2 min read

The Center for Drug Regulation and Research (CDRR) is the specialized office of the Food and Drug Administration (FDA) in the Philippines dedicated to regulating drugs and related pharmaceutical products. As a key Philippines drug Regulatory authority, CDRR is responsible for ensuring that medicines available in the country meet established standards for safety, efficacy, and quality for both human and veterinary use.

Main Responsibilities of the CDRR:

  • Approval and Licensing: CDRR evaluates applications for the registration, manufacture, importation, distribution, and sale of drugs and pharmaceutical products—including prescription medicines, over-the-counter drugs, vaccines, biologics, herbal and traditional medicines, veterinary medicines, and medical gases.
    The agency also oversees various aspects of FDA Philippines drug registration to ensure Regulatory compliance before products are marketed in the country.
  • Good Manufacturing Practice (GMP) Monitoring: Before drugs can be imported or sold in the Philippines, CDRR ensures that manufacturers comply with Good Manufacturing Practice standards through documentation, inspection, and ongoing monitoring.
  • Post-Market Surveillance: After products are launched in the market, CDRR monitors their continued safety, quality, and performance through post-market surveillance activities. These include tracking adverse drug reaction (ADR) reports, conducting pharmacovigilance activities such as the collection, assessment, and monitoring of adverse drug reactions and other product safety information, overseeing drug recalls, inspecting product quality, and responding to complaints, safety concerns, and emerging risks associated with marketed pharmaceutical products.
  • Regulatory Coordination: CDRR works closely with other government health bodies and internal FDA offices to set standards, issue advisories, conduct safety investigations, and coordinate industry compliance.
  • Public and Industry Guidance: The agency provides official procedures, licensing requirements, and guidance materials for industry stakeholders, health professionals, and the public regarding drug safety and Regulatory compliance.

Scope Covered by CDRR:

The Center for Drug Regulation and Research (CDRR) regulates a broad range of pharmaceutical and healthcare products, including:

  • Human pharmaceuticals (both prescription and non-prescription)
  • Vaccines and biologics
  • Veterinary products
  • Herbal and traditional medicines
  • Medical gases for human use

How CDRR Interacts with Stakeholders:

  • Issues licenses and certificates for establishments and product registrations.
  • Conducts and approves assessments for foreign and local manufacturers.
  • Provides official channels for Regulatory submissions, recalls, and safety reports.
  • Publishes advisories and guidelines to clarify standards and processes for compliance.

As a leading Philippines drug Regulatory authority, CDRR also plays a key role in maintaining Regulatory transparency and strengthening pharmaceutical oversight in the country.

Conclusion 

The Center for Drug Regulation and Research (CDRR) serves as the primary  center that oversee pharmaceutical product safety in the Philippines. From product registration and GMP monitoring to post-market surveillance and stakeholder guidance, CDRR plays a vital role in supporting a safe and effective pharmaceutical ecosystem.

With evolving Regulatory expectations and increasing compliance requirements, pharmaceutical companies must ensure alignment with FDA Philippines drug registration procedures and local Regulatory standards to achieve successful market entry and long-term compliance.

Click here to know more about our services: Medicinal Products Regulatory Support in Philippines | Freyr - Global Regulatory Solutions and Services Company

To learn more about how Freyr can support your Regulatory needs in Philippines write to us at sales@freyrsolutions.com.